Hepatotoxicity of drugs and chemicals;Foie, médicaments et agents chimiques

Gastroenterologie Clinique et Biologique

Volumn 33, Issue 12, 2009, Pages 1136-1146

  Larrey, D ^a  

^a HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPHATIC HYDROCARBON; AMIODARONE; ANALGESIC, ANTIINFLAMMATORY, ANTIRHEUMATIC AND ANTIGOUT AGENTS; ANESTHETIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; CAPTOPRIL; CARDIOVASCULAR AGENT; CISPLATIN; CYTARABINE; DERMATOLOGICAL AGENT; DILTIAZEM; ETOPOSIDE; FLECAINIDE ACETATE; GASTROINTESTINAL AGENT; HERBACEOUS AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; MERCAPTOPURINE; MEXILETINE; MITOMYCIN; NIFEDIPINE; PAPAVERINE; PARACETAMOL; POLYCYCLIC AROMATIC HYDROCARBON; PSYCHOTROPIC AGENT; STEROID HORMONE; TIOGUANINE; UNINDEXED DRUG;

AUTOIMMUNE HEPATITIS; CHOLESTATIC HEPATITIS; CYTOLYTIC HEPATITIS; DRUG OVERDOSE; HEPATITIS A; HEPATITIS B; HUMAN; LIVER FAILURE; LIVER TOXICITY; SHORT SURVEY; TOXIC HEPATITIS; WILSON DISEASE;

DRUG-INDUCED LIVER INJURY; HUMANS;

EID: 71149090149     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2009.10.003     Document Type: Short Survey

References (40)

1. Zimmerman H.J. The adverse effects of drugs and other chemicals on the liver. 2nd edn (1999), Lippincott Williams & Wilkins Eds
2. Larrey D. Drug-induced liver diseases. J Hepatol 32 Suppl. 1 (2000) 77-88
3. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Sem Liv Dis 22 (2002) 145-155
4. Kaplowitz N., and DeLeve L.D. Drug-induced liver disease (2007), Informa healthcare, New-York, London
5. Biour M. michel.biour@chusa.jussieu.fr.
6. Larrey D. Hepatotoxicity of herbal medicines. J Hepatol 26 Suppl. 1 (1997) 47-51
7. Larrey D. Complementary and alternative medicine hepatotoxicity. In: Andrade J.R. (Ed). International Hepatology Updates (2007), Parmanyer Publications, Barcelona 125-135
8. Stickel F., Patsenker E., and Schuppan D. Herbal heptotoxicity. J Hepatol 43 (2005) 901-910
9. Tolman K.G., and Dalpiaz A.S. Occupational and environmental hepatotoxicity. In: Kaplowitz N., and DeLeve L.D. (Eds). Drug-induced liver disease (2007), Informa Healthcare, New-York, London 755-770
10. Sgro C., Clinard F., Ouazir K., Chanay H., Allard C., Guillemet C., et al. Incidence of drug induced hepatic injuries. A french population-based study. Hepatology 36 (2002) 451-455
11. Lee W.M., Squires Jr. R.H., Nyberg S.L., Doo E., and Hoofnagle J.H. Acute liver failure: summary of a workshop. Hepatology 47 (2008) 1401-1415
12. Chalasani N., Fontana R.J., Bonkowsky H.L., Watkins P., Davern T., Serrano J., et al. Causes, clinical features and outcomes from a prospective study of drug-induced liver injury in the United states. Gastroenterology 135 (2008) 1924-1934
13. Pessayre D., and Larrey D. Drug-induced liver injury. In: Rodes J. (Ed). Textbook of Hepatology. 3rd edition (2007), Blackwell 211-1268
14. Lee W.M. Drug-induced hepatotoxicity. N Eng J Med 349 (2003) 474-485
15. Larrey D. Pathologies hépatiques mitochondriales. Gastroenterol Clin Biol 25 Suppl. 4 (2001) 117-122
16. Larrey D., and Pageaux G.P. Drug-induced liver failure. Eur J Gastroenterol Hepatol 17 (2005) 141-143
17. Watelet J., laurent V., Bressenot A., Bronowicki J.P., Larrey D., and Peyrin-Biroulet L. Toxicity of chronic paracetamol ingestion. Aliment pharmacol Ther 26 (2007) 1543-1544
18. Larrey D. Is there a risk to prescribe paracetamol at therapeutic doses in patients with acute or chronic liver disease?. Gastroneterol Clin Biol 30 (2006) 753-755
19. Louvet A., Boitard J., Dharancy S., Duriez A., Deltenre P., Paris J.C., et al. Problems with therapeutic acetaminophen use in excessive drinkers. Gastroenterol Clin Biol 30 (2006) 769-774
20. Watkins P., Seligman P.J., Pears J.S., Avigan M.I., and Senior J.R. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 48 (2008) 1680-1689
21. Lee W., Larrey D., Olsson R., lewis J.H., Keisu M., Auclert L., et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug safety 28 (2005) 351-370
22. Larrey D., and Pageaux G.P. Genetic predisposition to drug-induced hepatotoxicity. J Hepatol 26 (1997) 12-21
23. Criteria of drug-induced liver disorders. Report of an International Consensus Meeting. J Hepatol 1990;272-276.
24. Danan G., and Benichou C. Causalty assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 46 (1993) 1331-1336
25. Benichou C., Danan G., and Flahault A. Causality assessment of adverse reactions to drug - II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 46 (1993) 1331-1336
26. Lee W.M. Assessing causality in drug-induced liver injury. J Hepatol 33 (2000) 1003-1005
27. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 33 (2001) 308-309
28. Maria V.A.J., and Victorino R.M.M. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 26 (1997) 664-669
29. Aithal G.P., Rawlins M.D., and Day C.P. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol 33 (2000) 949-952
30. Lucena I., Camargo R., Andrade J., Perez-Sanchez C.J., and Sanchez De La Questa F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 33 (2001) 123-130
31. Lewis J.H., Larrey D., Olsson R., Lee W.M., and Keisu M. Utility of thr Roussel Uclaf causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: Evaluation of the direct thrombin inhibitor ximelagatran. Int J Pharmacol Ther 46 (2008) 327-339
32. Cantrell F.L. Look what I found! Poison hunting on eBay. Clin Toxicol 43 (2005) 375-379
33. Larrey D. Maladies hépatiques médicamenteuses. Aspects épidémiologiques, diagnostiques et cliniques. Encyclopédie médicochirurgicale, Hépatologie 2003, 7-015 -M-40:1-10.
34. Larrey D. Hépatotoxicité des médicaments immunosuppreseurs. Gastronterol Clin Biol 32 (2008) 194-204
35. Pirastu R., Comba P., Reggiani A., Foa V., Masina A., and Maltoni C. Mortality from liver disease among Italian vinyl chloride monomer/polyvinyl chloride manufacturers. Am J Med 17 (1990) 155-161
36. Barberino J.L., Carvalho F.M., Silvany-Neto A.M., et al. Liver changes in workers at n oil refinery and in a reference population in the state of Bahia Brezil. Rev Panam Salud Publica 17 (2005) 30-37
37. Abraham K., Geusau A., Tosun Y., Helge H., Bauer S., and Brockmoller J. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurements oh hepatic cytochrome P450 1A2 induction. Clin Pharmacol Ther 72 (2002) 63-174
38. Fernandez-D'Pool J., and Orono-Osorio A. Liver function in workers occupationally exposed to mixed organic solvents in a petrochemical industry. Invest Clin 42 (2001) 87-106
39. Bolt H.M. Vinyl chloride - A classical industrial toxicant of new interest. Crit Rev Toxicol 35 (2005) 307-323
40. NIOSH. Pocket Guide to chemicals hazards. US Government Printing Office, ed US Department of Heath and Human Services Publications 94-116. US Government Printing Office, 1994.